M.D., Ph.D., Professor & Chairman, Radiology, Stanford University
Dr. Gambhir is the Virginia & D.K. Ludwig Professor of Cancer Research, Chairman of Radiology at Stanford University School of Medicine. Dr. Gambhir’s lab has focused on interrogating fundamental molecular events in living subjects. He has developed and clinically translated several multimodality molecular imaging strategies including imaging of gene and cell therapies.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: Cancer immunotherapy, and in particular PD-(L)1 blockade, have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malignancies, it has become clear that they are not sufficiently active for many patients. Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has highlighted the potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action. There are multiple potential rational combinations using an immunotherapy backbone, including existing treatments such as radiotherapy, chemotherapy or molecularly targeted agents, as well as other immunotherapies. Rational trial designs based on a clear understanding of tumor biology and drug pharmacology remain critical.